IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

The real market implication is not “healthcare vs healthcare,” but which factor you are buying inside the sector. A cap-weighted global wrapper naturally concentrates passive support into the highest-quality cash generators, so names like LLY, JNJ, and ABBV should continue to receive the cleanest flow support when investors rotate defensively. By contrast, equal-weight U.S. healthcare is a hidden small-/mid-cap growth bet; that means more upside if sentiment broadens, but also more forced selling of recent winners and more liquidity stress in weaker holdings when the tape turns risk-off.

That structure matters over three horizons. Over days, ETF flows can create temporary price dislocations around rebalances, especially in names that have drifted farthest from target weights. Over 1-3 months, the key catalyst is whether the market keeps favoring large-cap quality or starts rewarding lower-quality beta in biotech/tools; that will determine whether RSPH’s higher beta is a feature or a bug. Over 6-18 months, the more durable winner is likely the vehicle that best matches the regime: defensive mega-cap pharma in a slowing growth world, or equal-weight innovation exposure if rates fall and clinical/risk appetite improves.

The consensus is probably overrating headline yield and underweighting factor content. IXJ’s higher distribution is mostly a byproduct of mature pharma concentration, not a free lunch, while RSPH’s lower drawdown history is not a guarantee if the underlying small-name cohort de-rates. The more interesting contrarian point is that if you want true healthcare defensiveness, RSPH is the wrong expression; if you want innovation beta, you may be better off owning the individual names directly instead of paying 40 bps for an equal-weight wrapper.